21 January 20213 minute read

DLA Piper advises Haemonetics in its acquisition of Cardiva Medical

DLA Piper represented Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative medical solutions to drive better patient outcomes, in its acquisition of Cardiva Medical, Inc., an industry-leading manufacturer of vascular closure systems based in Santa Clara, California, for US$475 million at closing and up to an additional US$35 million in contingent consideration based on sales growth.

The acquisition, which is subject to customary closing conditions and is expected to be completed in the first quarter of 2021, will enhance Haemonetics Corporation’s hospital portfolio and presence in the large and growing interventional cardiology and electrophysiology markets.

 

The DLA Piper team representing Haemonetics was led by partner Adam Ghander (Boston) and included partners Nathaniel McKitterick (Silicon Valley), William Bartow (Philadelphia), Eric Christofferson (Boston), Kristi Kung (Northern Virginia) and Ryan Vann (Chicago); of counsel Nia Brown (Washington, DC); senior attorney Jerami Davidson (Boston); and associates Kurtis Weaver, Tim Fuhriman, Michael Jamieson (all of Boston) and Karun Ahuja (Chicago).

 

With more than 1,000 corporate lawyers globally, DLA Piper helps clients execute complex cross-border transactions seamlessly while supporting clients across all stages of development. The firm has been rated number one in global M&A volume for 11 consecutive years, according to Mergermarket.

 

DLA Piper advises on all aspects of the life sciences sector, combining subject matter experience with considerable knowledge of the scientific, medical, regulatory, commercial and enforcement environments facing biopharmaceutical, medical device, research and diagnostics clients. Recognizing that clients’ needs vary, the firm rapidly organizes and customizes client service teams, whether for a large pharmaceutical company, a mid-sized medical device client or a development-stage biotech company.

Print